Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Claire Harrison, Marina Kremyanskaya, Prithviraj Bose, Vikas Gupta, Raajit K Rampal, Jonathan Lambert, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Sandra Klein, Soumik Dutta, John Mascarenhas

Blood (2022) 140 (Supplement 1): 9659–9662.

https://doi.org/10.1182/blood-2022-157735

Published: 2022

Journal Articles

Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

Chiara Maccari, Benedetta Sordi, Paola Guglielmelli, Manjola Balliu, Alessandro Atanasio, Carmela Mannarelli, Giulio Capecchi, Ilaria Sestini, Giacomo Coltro, Giada Rotunno, Eva Angori, Filippo C. Borri, Natasha Szuber, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 3955–3956.

https://doi.org/10.1182/blood-2022-156773

Published: 2022

Journal Articles

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Paola Guglielmelli, Barbara Mora, Francesca Gesullo, Francesco Mannelli, Giuseppe Gaetano Loscocco, Leonardo Signori, Chiara Pessina, Fabiana Pancani, Ilaria Colugnat, Raffaela Aquila, Elena Nacca, Paolo Cicogna, Francesco Passamonti, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 1788–1789.

https://doi.org/10.1182/blood-2022-156781

Published: 2022

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Paola Guglielmelli, Fiorenza Irushani Vanderwert, Simone Romagnoli, Giacomo Coltro, Giuseppe Gaetano Loscocco, Francesco Mannelli, Laura Calabresi, Giulia Gentili, Giada Rotunno, Niccolò Bartalucci, Valentina Boldrini, Emanuela Sant'Antonio, Danilo Tarantino, Marco Pieraccioli, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 832–833.

https://doi.org/10.1182/blood-2022-156776

Published: 2022

Journal Articles

The Immature Morphology of the Megakaryocytes Present in the Bone Marrow of Patients with Myelofibrosis Reflects Changes in the Frequency of Functionally Distinctive Subpopulations

Francesca Arciprete, Maria Zingariello, Maria Mazzarini, Paola Verachi, Fabrizio Martelli, Anna Crescenzi, Elisabetta Cerchiara, Giuseppe Avvisati, Paola Guglielmelli, Manjola Balliu, Alessandro Vannucchi, Anna Rita Migliaccio

Blood (2022) 140 (Supplement 1): 12148–12149.

https://doi.org/10.1182/blood-2022-157526

Published: 2022

Journal Articles

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Raajit K Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Ruben Mesa, Gozde Colak, Qing Li, Sandra Klein, Claire Harrison

Blood (2022) 140 (Supplement 1): 586–589.

https://doi.org/10.1182/blood-2022-158147

Published: 2022

Journal Articles

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison

Blood (2022) 140 (Supplement 1): 1523–1525.

https://doi.org/10.1182/blood-2022-159409

Published: 2022

Journal Articles

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Ruben Mesa, Srdan Verstovsek, Uwe Platzbecker, Vikas Gupta, David Lavie, Pilar Giraldo, Jean-Jacques Kiladjian, Stephen T Oh, Timothy Devos, Francesco Passamonti, Miklos Egyed, Alessandro Vannucchi, Andrzej Pluta, Donal P McLornan, Jun Kawashima, Mei Huang, Bryan Strouse, Claire Harrison

Blood (2022) 140 (Supplement 1): 3983–3985.

https://doi.org/10.1182/blood-2022-159636

Published: 2022

Journal Articles

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Ruben Mesa, Marina Kremyanskaya, Andrea Patriarca, Vikas Gupta, Francesca Palandri, Timothy Devos, Claire Harrison, Raajit K. Rampal, Moshe Talpaz, Alessandro Vannucchi, Andrew Kuykendall, Jean-Jacques Kiladjian, Srdan Verstovsek, Gozde Colak, Debarshi Dey, John Mascarenhas

Blood (2022) 140 (Supplement 1): 11056–11059.

https://doi.org/10.1182/blood-2022-159389

Published: 2022

Journal Articles

Serum TARC Concentration Kinetic in Classical Hodgkin Lymphoma during First-Line Treatment

Ilaria Romano, Benedetta Puccini, Leonardo Signori, Michela Zizza, Giacomo Coltro, Marianna Palazzo, Elettra Galli, Lara Mannelli, Alberto Bosi, Alessandro Vannucchi, Luca Nassi

Blood (2021) 138 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2021-148137

Published: 2021

Journal Articles

Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms

Paola Guglielmelli, Laura Calabresi, Chiara Carretta, Giada Rotunno, Sandra Parenti, Simone Romagnoli, Selene Mallia, Niccolò Bartalucci, Sebastiano Rontauroli, Chiara Chiereghin, Sara Castellano, Francesco Mannelli, Matteo G. Della Porta, Rossella Manfredini, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 56.

https://doi.org/10.1182/blood-2021-148315

Published: 2021

Journal Articles

Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis

Giacomo Coltro, Paola Guglielmelli, Giada Rotunno, Carmela Mannarelli, Chiara Maccari, Costanza Salvadori, Fiorenza Irushani Vanderwert, Francesco Mannelli, Cristina Salvati, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2021-148685

Published: 2021

Journal Articles

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Blood (2021) 138 (Supplement 1): 2568.

https://doi.org/10.1182/blood-2021-152267

Published: 2021

Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani

Blood (2021) 138 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2021-147618

Published: 2021

Journal Articles

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

Fiorenza Irushani Vanderwert, Benedetta Sordi, Francesco Mannelli, Boaz Palterer, Francesca Gesullo, Valentina Mecheri, Raffaella Santi, Carmela Mannarelli, Francesca Crupi, Roberta Zanotti, Federica Irene Grifoni, Chiara Elena, Roberta Parente, Massimo Triggiani, Pieri Lisa, Fabio Almerigogna, Paola Guglielmelli, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 1500.

https://doi.org/10.1182/blood-2021-148154

Published: 2021

Journal Articles

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)

John Mascarenhas, Claire N. Harrison, Jean-Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Vannucchi, Tymara Berry, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Aleksandra Rizo, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 1503.

https://doi.org/10.1182/blood-2021-148931

Published: 2021

Journal Articles

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, Jean-Jacques Kiladjian, Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2021-147543

Published: 2021

Journal Articles

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Nicola Vianelli, Giulia Benevolo, Alessandro Vannucchi, Claire N. Harrison, Michael Loschi, Haifa Kathrin Al-Ali, Massimiliano Bonifacio, Francisco Cervantes, Tomasz Wrobel, Giovanni Barosi, Jean-Jaques Kiladjian, Srdan Verstovsek, Ruben A. Mesa, Shelonitda Rose, Vishwanath Gharpure, Christopher Hernandez, Jun Zhang, Francesco Passamonti

Blood (2021) 138 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2021-147614

Published: 2021

Journal Articles

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Blood (2021) 138 (Supplement 1): 141.

https://doi.org/10.1182/blood-2021-150172

Published: 2021

NARROW

Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study

Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

JAK2 V617F Molecular Response to Ruxolitinib in Patients with PV and ET Is Associated with Lower Risk of Progression to Secondary Myelofibrosis

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

The Immature Morphology of the Megakaryocytes Present in the Bone Marrow of Patients with Myelofibrosis Reflects Changes in the Frequency of Functionally Distinctive Subpopulations

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib

Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy

Serum TARC Concentration Kinetic in Classical Hodgkin Lymphoma during First-Line Treatment

Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms

Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only